Section Arrow
Quote
TVRD.NASDAQ
- Tvardi Therapeutics Inc
Quotes are at least 15-min delayed:2025/11/19 06:25 EST
Pre Market
Last
 3.99
-0.13 (-3.16%)
Bid
3.5
Ask
6
High 3.99 
Low 3.99 
Volume 20 
Regular Hours
Last
 4.12
+0.09 (+2.23%)
Day High 
4.1999 
Prev. Close
4.03 
1-M High
6.43 
Volume 
148.65K 
Bid
3.5
Ask
6
Day Low
3.93 
Open
4 
1-M Low
3.85 
Market Cap 
37.79M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.14 
20-SMA 4.53 
50-SMA 20.58 
52-W High 43.65 
52-W Low 3.85 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.25/-1.52
Enterprise Value
38.07M
Balance Sheet
Book Value Per Share
3.51
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
20.97M
Operating Revenue Per Share
5.94
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CANFCan-Fite BioPharma Ltd0.3801+0.0181+5.00%-- 
Pre Market 0.363 -0.0171 -4.50%
ASBPAspire Biopharma Holdings Inc.0.1057+0.0144+15.77%-- 
Pre Market 0.1018 -0.0039 -3.69%
OLMAOlema Pharmaceuticals20.14+11.62+136.38%-- 
Pre Market 18.88 -1.26 -6.26%
CMNDClearmind Medicine0.2164-0.0605-21.85%0.16PE
Pre Market 0.2332 +0.0168 +7.76%
APLTApplied Therapeutics0.2984+0.0142+5.00%-- 
Pre Market 0.2791 -0.0193 -6.47%
Quotes are at least 15-min delayed：2025/11/19 06:25 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.